Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q2 2022 · 10-Q
Revenue—
Net Income-$469.30K-$469.30KN/M vs Q2 2021 EPS Diluted-$1.36-$1.36N/M vs Q2 2021 Operating Income-$469,304N/M Operating Cash Flowderived-$360,064N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 11, 2022 · 42 d after period end